en POLSKI
eISSN: 2084-9834
ISSN: 0034-6233
Reumatologia/Rheumatology
Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Reviewers Abstracting and indexing Subscription Contact Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank


Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
6/2008
vol. 46
 
Share:
Send email
Share:
abstract:

Review paper
Efficacy and safety of TNF blockers in ankylosing spondylitis in randomized, controlled trials and prolonged open label studies

Ewa Stanisławska-Biernat

Reumatologia 2008; 46, 6: 361–366
Online publish date: 2009/01/21
View full text Get citation
 
Ankylosing spondylitis (AS) is a chronic inflammatory disease in the course of which we observe diminution of range of motion of the spine and invalidity. Randomized controlled trials and prolonged open label studies have confirmed the efficacy and safety of a new group of drugs in treatment of ankylosing spondylitis. By means of a variety of mechanisms, TNF inhibitors reduce activity of one of the proinflammatory cytokines, TNF-α. This article presents a systematic review of published trials, the results of which prove the superiority of adalimumab, etanercept and infliximab over traditional methods of treatment. Introduction of TNF blockers represents a major advance in therapy of ankylosing spondylitis.
keywords:

ankylosing spondylitis, treatment, TNF blockers, randomized controlled trials, etanercept, adalimumab, infliximab
EVENTS/KONFERENCJE
BOOKS/KSIĄŻKI



Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.